Delivery Order SPE2DB24D2205-SPE2DB25FEHKF
- Not listed
- The Defense Logistics Agency awarded a $11,174.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for August 8, 2025. This competitively awarded contract, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a firm fixed-price delivery order by the Defense Logistics Agency's Medical Supply Chain on August 23, 2025, for the supply of Xeomin 100 Unit vials. The contract ceiling value is $11,174.80, with an ultimate completion date of September 12, 2025. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside contract awarded through competitive procurement, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for the supply of Xeomin 200 Unit vials. This competitively awarded, firm fixed price contract was issued on August 27, 2025, with an ultimate completion date of September 18, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a non-set-aside procurement, this delivery order was competed among qualified...
- The Defense Logistics Agency awarded a $13,968.50 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on July 24, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as the prime contractor fulfilling this...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,174.80 by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xeomin 100 Unit Vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and represents a non-competitive set-aside award. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for the supply of Xeomin 200 unit vials, with performance to be completed by August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competed among all eligible contractors....
- The Defense Logistics Agency awarded a delivery order valued at $23,467.08 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 Unit Vials, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's...
- This delivery order, awarded July 25, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Xeomin 100 Unit Vials with a ceiling value of $1,396.85 and an ultimate completion date of August 15, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of XEOMIN 100 UT vials valued at $11,174.80. This is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and was awarded through open competition without set-aside provisions. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $43,134 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a pharmaceutical product used in medical treatments. This non-set-aside competitive award was issued on August 14, 2025, with an ultimate completion date of September 5, 2025. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract under...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHKFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeomin 200 Unit Vials with a ceiling value of $2,793.70 and an ultimate completion date of October 2, 2025. This firm fixed price, competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen maintains an extensive portfolio of medical product deliveries to support military and veteran healthcare systems. The Xoemin supply supports the broader pharmaceutical prime vendor program, enabling DLA to source specialty medications and injectable treatments for Defense Health Agency customers and other federal healthcare beneficiaries worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/11/25 |